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Abstract
Introduction: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory disorder of unknown etiology. In
children and adolescents CNO predominantly affects the metaphyses of the long bones, but lesions can occur at
any site of the skeleton. Prospectively followed cohorts using a standardized protocol in diagnosis and treatment
have rarely been reported.
Methods: Thirty-seven children diagnosed with CNO were treated with naproxen continuously for the first
6 months. If assessment at that time revealed progressive disease or no further improvement, sulfasalazine and
short-term corticosteroids were added. The aims of our short-term follow-up study were to describe treatment
response in detail and to identify potential risk factors for an unfavorable outcome.
Results: Naproxen treatment was highly effective in general, inducing a symptom-free status in 43% of our
patients after 6 months. However, four nonsteroidal anti-inflammatory drug (NSAID) partial-responders were
additionally treated with sulfasalazine and short-term corticosteroids. The total number of clinical detectable lesions
was significantly reduced. Mean disease activity estimated by the patient/physician and the physical aspect of
health-related quality of life including functional ability (global assessment/childhood health assessment
questionnaire and childhood health assessment questionnaire) and pain improved significantly. Forty-one percent
of our patients showed radiological relapses, but 67% of them were clinically silent.
Conclusions: Most children show a favorable clinical course in the first year of anti-inflammatory treatment with
NSAIDs. Relapses and new radiological lesions can occur at any time and at any site in the skeleton but may not
be clinically symptomatic. Whole-body magnetic resonance imaging proved to be very sensitive for initial and
follow-up diagnostics.
Introduction
Chronic nonbacterial osteomyelitis (CNO) is an inflam-
matory, non-infectious disorder of the musculoskeletal
system of unknown etiology. Both single and multiple
lesions and recurrence have been described [1-3]. In
children and adolescents CNO predominantly affects the
metaphyses of the long bones, but lesions can occur at
any site of the skeleton. Other organs including the
skin, eyes, gastrointestinal tract and lungs can also be
affected by inflammation [4-7]. Chronic recurrent multi-
focal osteomyelitis (CRMO) is considered the pediatric
form of the SAPHO syndrome (synovitis, acne, pustulo-
sis, hyperostosis and osteitis) and is the most severe
form of CNO [8,9]. Histological bone lesions in unifocal
and multifocal CNO, as well as in SAPHO syndrome,
show similar inflammatory features [10,11].
There have been attempts to classify patients into
defined groups (unifocal nonrecurrent, unifocal recur-
rent, multifocal nonrecurrent, multifocal recurrent) in
order to set up diagnostic criteria and to find prognostic
indicators [12,13]. CNO is diagnosed by exclusion of dif-
ferential diagnoses such as malignancy, benign tumorous
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bone lesions, bacterial osteomyelitis, bone bruise or frac-
ture, osteonecrosis and osteopetrosis. Currently, diagno-
sis is made by the clinical picture, laboratory data,
radiological and magnetic resonance imaging (MRI) stu-
dies, technetium bone scan, and microbial and histo-
pathologic analysis in a multidisciplinary approach. Until
now no standardized diagnostic criteria and therapeutic
guidelines or standards exist. Furthermore, there are no
generally accepted treatment protocols available.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have
been recommended as a first-line therapy and seem to
be safe and effective. Disease-modifying anti-rheumatic
drugs (DMARDs), steroids, bisphosphonates and TNF
blockers have also been used in severe disease manifes-
tations, frequent relapses and associated inflammatory
diseases [12,14-21]. Of note, bisphosphonates have also
been used recently as first-line therapy [14,15,20]. Since
treatment response using NSAIDs so far has been
described only in retrospectively evaluated cohorts, we
have initiated a prospective 5-year follow-up study. In
the present article we describe the follow-up in the first
year.
The aims of our short-term follow-up study were to
evaluate NSAID treatment in the first year by describing
clinical and whole-body (WB) MRI data and to identify
risk factors for an unfavorable course of disease. NSAID
treatment was expanded after 6 months using sulfasala-
zine and short-term steroids if treatment efficacy
seemed limited. This treatment step was based on pre-
vious experience [12,13,16,18]. Special emphasis was
placed on evaluation of a clinical scoring system, labora-
tory analysis and sequential WB-MRI in order to find
diagnostic and prognostic indicators that could be help-
ful in the clinical management and future evaluation of
different treatment strategies.
Materials and methods
Thirty-seven children (24 girls, 13 boys) diagnosed with
CNO were included who were newly diagnosed and
who had not received any anti-inflammatory or antibio-
tic therapy. The disease was assessed using a clinical
score, initial diagnostic biopsy, laboratory tests and mul-
tiple imaging including WB-MRI at 0, 3, 6 and
12 months. The CNO core set of outcome variables is
composed of the following five measures: erythrocyte
sedimentation rate (ESR), number of radiological lesions,
severity of disease estimated by the physician, severity of
disease estimated by the patient or parent, and the
childhood health assessment questionnaire (CHAQ).
The definition of improvement was as follows: for the
PedCNO30 (PedCNO50, PedCNO70) score, at least
30% (50%, 70%) improvement in at least three out
of five core set variables, with no more than one of
the remaining variables deteriorating by more than 30%
(50%, 70%).
Treatment with naproxen 15 mg/kg/day started at the
time of diagnosis/biopsy and continued throughout
12 months. In case of insufficient response after 6
months, sulfasalazine was added at 20 mg/kg/day as a
DMARD [14,19,20]. In addition, oral glucocorticoids
were administered for 1 week at 2 mg prednisone/kg/
day, followed by another week of tapering and disconti-
nuation (for more detailed description see Additional
file 1).
The study was approved by the local ethics committee.
Signed informed consent was obtained from the patients’
parents and from adolescent patients.
Results
Clinical features
Osteomyelitis
There was a mean delay of 5 months in making the
diagnosis after the first symptoms had appeared. In all
patients the disease onset was before 18 years of life,
ranging from 25 months to 16 years of age with a mean
age of 11.0 years. Eight patients showed a unifocal
lesion, and 29 had multifocal lesions - 27 at the time of
diagnosis, and two initially presented as a unifocal lesion
but developed additional bone lesions during the first
year of the disease. All together, 184 clinical foci (pain,
functional impairment or swelling) were detected over
1 year (initial, 79 foci; after 1 month, 38 foci; after
3 months, 27 foci; after 6 months, 21 foci; and after
12 months, 19 foci) - resulting in a mean of 1.0 (2.1 at
time of diagnosis, 1.1 after 1 month, 0.8 after 3 months,
0.6 after 6 months, and 0.5 after 1 year of treatment)
per patient, showing a significantly lower number in fol-
low-ups (analysis of variance (ANOVA), P < 0.05). The
number of clinical lesions in the thorax, spine, pelvis
and extremities were significantly less in the follow-ups
of months 3, 6, and 12, whereas the head involvement
remained unchanged (n = 1) on a low level (ANOVA,
P < 0.05). The head was clinically involved in 2.7%, the
extremities in 53.3%, the thorax in 19.6%, the spine in
6.5% and the pelvis in 17.9% of patients (Table 1).
At the time of diagnosis, 22% of patients complained
about morning stiffness lasting 2 to 60 minutes (mean
12.5 minutes), 67% showed a relieving posture, 37% pre-
sented local bone/tissue swelling and 26% presented
asymmetry of the extremities or thorax. Local pain in
the affected bones was the leading symptom in 74% and
was recorded with a mean score of 4.4 (unifocal 3.4,
multifocal 4.8) using a 10 cm visual analog scale (VAS).
Severity of disease was estimated by the parents/patient
as 5.0 (unifocal, 4.5; multifocal, 5.1) on the VAS, and by
the examiner as 4.7 (unifocal, 3.8; multifocal, 5.0). The
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global assessment/CHAQ was estimated as 3.8 (unifocal,
2.0; multifocal, 4.5), and the CHAQ score was 0.7 (uni-
focal, 0.1; multifocal, 1.0) at initial presentation.
Arthritis
Initially 14/37 (38%) patients were diagnosed with
arthritis of joints adjacent to the lesion by physical
examination and/or MRI. We did not diagnose arthritis
in patients who were initially arthritis free during the
first year. After 3 months arthritis was still present in all
of these 14 patients, after 6 months in seven patients,
and after 12 months three patients were still affected by
arthritis.
Associated diseases
In 24% (9/37) of the patients, CNO-associated diseases
were present.
Skin lesions such as palmoplantar pustulosis (3/6),
acne conglobata (2/6) or psoriasis/psoriatic afflictions of
nails (1/6) were present in 17% of patients (n = 6). In
general, skin lesions tended to improve during the first
year using emollients. Four out of these six patients had
complete remission of their skin lesion.
Chronic inflammatory bowel disease was diagnosed in
one patient (3%) initially. He was affected by Crohn’s
disease and showed multifocal and chronic inflamma-
tory bone lesions. The patient needed a multimodal
anti-inflammatory, immunosuppressant and immuno-
modulating therapy (naproxen, sulfasalazine, predni-
sone/budesonid, azathioprine) focusing on both clinical
entities from the beginning because of many osteo-
inflammatory lesions (radiological, 19 lesions; clinical,
five lesions) and severe bowel disease. In this patient,
intestinal symptoms and signs of chronic bowel
inflammation soon improved significantly, reaching clin-
ical remission after 3 months. CNO disease activity,
however, could not be brought into remission in parallel.
Relapses, radiological signs of active inflammation and
even complications such as stress tibial fractures could be
detected. The total numbers of the patient’s radiological
lesions were lower at month 3 (n = 7) but were raised at
months 6 to 9 because of two new radiologic lesions in the
extremities, and were lower again at month 12 (three
lesions detectable in WB MRI). Of interest, at months 3, 6
and 12 the patient did not show any clinical detectable
lesion. The patient did not show Crohn’s disease-associated
CARD15 gene variants (R702W, 1007fs, G908R).
Hypophosphatasia was diagnosed in two patients (5%).
In these patients clinically affected by CNO we found
reduced serum tissue nonspecific alkaline phosphatase
activity. No patient had premature loss of teeth, but one
patient had a short stature [16].
Laboratory tests
Laboratory data (Table 2) showed a mean of 7,961 leu-
cocytes/μl (range 4,360 to 17,030/μl), a mean ESR of 16
mm/hour (range 3 to 110 mm/hour, normal <20 mm/
hour), a mean C-reactive protein level of 0.7 mg/dl
(range 0 to 13.9 mg/dl, normal <0.5 mg/dl), and a mean
ferritin level of 36 μg/l (range 3 to 150 μg/l, normal
value 2.3 to 63 μg/l). The mean value for leucocytes and
ferritin was in the normal range in initial and follow-up
diagnostics. Ferritin levels, however, were significantly
higher in the initial examination versus follow-ups
(ANOVA,P < 0.05). C-reactive protein in the initial
laboratory data was slightly raised in multifocal CNO
Table 1 Course of disease: clinically and radiologically identified lesions located in all body regions
Location 0 months 3 months 6 months 12 months Total in first year
Clinical lesions 2.1 0.8 0.6 0.5 1.0
Mean
Absolute number 79 27a 21a 19a 184
Head 1 (1.3) 1 (3.7) 1 (4.8) 1 (5.3) 4 (2.7)
Extremities 38 (48.1) 15a (55.6) 14a (66.7) 10a (52.6) 77 (53.3)
Thorax 15 (19.0) 6a (22.2) 2a (9.5) 4a (21.1) 27 (19.6)
Spine 7 (8.9) 1a (3.7) 2a (9.5) 1a (5.3) 11 (6.5)
Pelvis 18 (22.8) 4a (14.8) 2a (9.5) 3a (15.8) 27 (17.9)
Radiological lesions
Mean 5.0 3.7 2.5 2.2 3.4
Absolute number 184 121 89a 81a 475
Head 1 (0.5) 1 (0.8) 1 (1.1) 1 (1.2) 4 (0.8)
Extremities 91 (49.5) 78 (64.5) 66 (74.1) 63 (77.7) 298 (62.7)
Thorax 19 (10.3) 11 (9.1) 10 (11.2) 6a (7.4) 46 (9.7)
Spine 27 (14.7) 9 (7.4) 2a (2.2) 2a (2.5) 40 (8.4)
Pelvis 46 (25.0) 22 (18.2) 10a (11.2) 9a (11.1) 87 (18.3)
Results presented as absolute numbers (%). Statistical analysis performed using analysis of variance. Head involvement was noted in one patient, where the os
zygomaticum was affected. aP < 0.05 versus month 0.
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(2.5 mg/dl) and in unifocal CNO (1.7 mg/dl), and nor-
malized in the following months (total CNO ANOVA,
P < 0.05, data of months 1, 3, 6 and 12 versus month
0). The ESR initially was moderately raised in multifocal
CNO (32 mm/hour) but not in unifocal CNO (18 mm/
hour), and was less in the following follow-ups (total
CNO ANOVA, P < 0.05, data of months 1, 3, 6 and 12
versus month 0).
As mentioned initially, elevated inflammation markers
were noticed in an adolescent with CRMO and acute
presentation of inflammatory bowel disease (C-reactive
protein, 13.9 mg/dl; ESR, 40 mm/hour; ferritin,
117 μg/l), and in patients with large numbers of radiolo-
gical inflammatory bone lesions, especially with involve-
ment of the spine or diaphyses of long bones. Patients
initially presenting with a higher number of radiological
lesions also presented with a higher ESR (P < 0.0009,
correlation coefficient r = 0.5) (Figure 1).
All patients had normal serum IgG levels (mean 1,181
mg/dl) except one patient with CRMO, who initially had
raised levels (2,147 mg/dl) that normalized in the fol-
lowing examinations. At diagnosis, serum IgA levels
were raised moderately in five cases and raised strongly
in one case (mean 186 mg/dl, range 49 to 612 mg/dl)
but all showed normal values later on. Serum IgM levels
were slightly reduced over time in 10 patients. There
was no patient with raised levels (mean 106 mg/dl,
range 20 to 285 mg/dl).
Totals of 51.3% and 8.1% of patients had antinuclear
antibody (ANA) levels with a titer ≥1:80 and ≥1:160,
respectively. These levels of ANA were not different
when compared with a healthy control group of 88 age-
matched children (data not shown). Eight percent were
HLA-B27-positive. No patient was rheumatoid factor
IgM-positive. There was no significant difference in the
prevalence of ANAs and the presence of RF and HLA-
B27 between unifocal CNO and multifocal CNO.
Imaging techniques
Conventional X-ray scans (only initially) and MRI scans
(0, 3, 6, and 12 months) of the region of clinical lesions
were performed in all patients. Twenty-one patients
(57%) received a WB-MRI at time of diagnosis and after
3, 6 and 12 months of treatment. All together, 475 radi-
ologically defined inflammatory lesions were detected
during the first year (initial, 184 lesions; after 3 months,
121 lesions; after 6 months, 89 lesions; after 12 months,
81 lesions), resulting in an overall mean of 3.4 (5.0 at
Table 2 Laboratory features of patients presenting with chronic nonbacterial osteomyelitis
Characteristic 0 months 1 month 3 months 6 months 12 months Mean (median)
in first year
Leukocytes (/μl) 8,324 (8,150) 8,041 (7,770) 8,127 (8,270) 7,734 (7,575) 7,581 (7,430) 7,961 (7,779)
Erythrocyte sedimentation rate (mm/first hour) 28 (24) 15a (11) 11a (10) 13a (10) 12a (10) 28 (10)
C-reactive protein (mg/dl) 2.4 (1.4) 0.1a (0.0) 0.3a (0.0) 0.3a (0.0) 0.2a (0.0) 0.7a (0.0)
Ferritin (μg/l) 54 (37) 35a (32) 31a (27) 29a (26) 31a (22) 36a (27)
Results presented as mean (median). Statistical analysis performed using analysis of variance. aP < 0.05 versus month 0.
Figure 1 Correlation of the number of radiological lesions with the erythrocyte sedimentation rate. Regression line depicts the 95%
confidence interval. Results presented as absolute numbers. Correlation coefficient r = 0.5, P < 0.0009. ESR, erythrocyte sedimentation rate.
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time of diagnosis, 3.7 after 3 months, and 2.5 after 6 and
12 months of treatment) per patient (Table 1). The head
was involved in 0.8%, the extremities in 62.7%, the
thorax in 9.7%, the spine in 8.4%, and the pelvis in
18.3%. Table 1 shows the course of disease concerning
radiological lesions (means) in the first year of
treatment.
Most bone lesions of the extremities were localized in
the metaphyses of the long bones close to the growth
plate - only five patients showed lesions affecting the
diaphyses. Inflammatory bone lesions were accompanied
with local soft tissue involvement including periosteal,
articular and muscular inflammation. Three patients
developed pathological bone fractures (spine, two cases;
extremities, one case) during the first year. The stress
fractures in the distal tibia of both sides in one patient
and fractures in the spine of two patients showed a
good outcome. Fractures in the extremities did not
result in any dislocation, axis deviation or other pro-
blems. Patients with spine fractures did not show an
active inflammatory process in this region at month 12:
one was totally lesion-free, and the other patient showed
a lower number of radiological inflammatory bone
lesions at month 12. A residual radiological damage
could be detected in both patients at month 12 without
being symptomatic. Figure 2 shows a WB-MRI with
typical inflammatory radiological bone lesions of one
patient with CRMO and Crohn’s disease at time of
diagnosis.
WB-MRI proved to be more sensitive during the study
than scintigraphy. Technetium bone scintigraphy has
therefore no longer been included in the initial diagnos-
tic work-up after WB-MRI became available. Eleven
patients (30%) initially underwent skeletal scintigraphy
as WB-MRI had not been available.
Course of disease
Treatment
All patients were treated with naproxen (15 mg/kg/day)
for 12 months starting shortly after biopsy. Naproxen
was well tolerated during the first year of treatment
without any reported adverse events. Naproxen treat-
ment was generally highly effective, inducing a clinical
asymptomatic status in 43% (16/37) of our patients after
6 months. Assessment after 6 months revealed progres-
sive disease or no further improvement in four patients.
Sulfasalazine in two single doses of 20 mg/kg/day was
therefore added, always accompanied by a 2-week
course of oral glucocorticoid treatment (prednisone
2 mg/kg/day for 1 week initially, discontinued stepwise
afterwards). In one patient with chronic inflammatory
bowel disease co-manifestation, a multimodal anti-
inflammatory and immunomodulating therapy with
naproxen, sulfasalazine and prednisone/budesonid
Figure 2 Whole-body magnetic resonance imaging of chronic
nonbacterial osteomyelitis. Whole-body magnetic resonance
imaging of one patient with extensive multifocal inflammatory
radiological lesions at time of diagnosis: T2-weighted images with
fat suppression (inverse recovery sequences, TIRM). The os sacrum
and the acetabulum (all three osseous parts) did show severe signal
elevation in the TIRM sequence. Further lesions are seen in the
metaphyses of both proximal and distal femurs, proximal tibias and
fibulas predominantly in the epiphyses/metaphyses and in the
distal tibia and fibula with periosteal edema on the right side,
supporting the clinical diagnosis of periostitis and arthritis. Signal
alterations/edema in the skeleton of the feet can be noted at the
basis of os metatarsale V, os metatarsale I and in the tuber calcanei
on the right side; on the left side, the basis and the proximal parts
of os metatarsale I and the distal os metatarsale V and the proximal
phalanx V are affected.
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followed by azathioprine was started from the beginning.
By using DMARD/glucocorticoid treatment we were
able to induce a clinical lesion-free status in two
patients, a decreased number of lesions in one patient,
and two patients showed an unchanged number of clini-
cal lesions. We did not detect new or more clinical
lesions after adding sulfasalazine.
Further on after starting additional treatment with sul-
fasalazine, the CNO overall disease activity estimated by
the parents/patients and by the physician on the VAS
and the CHAQ score could be improved (overall disease
activity - physician and patient: after 6 months, 1.5; after
12 months, 1; and CHAQ score: after 6 months, 0.1;
after 12 months, 0), demonstrating a similar clinical out-
come when compared with all patients. The total num-
ber of radiological lesions decreased in two patients,
persisted unchanged in one patient but increased in two
patients.
Prognosis
Most children did show a favorable clinical outcome
after 1 year of treatment. After 12 months no patient
complained about morning stiffness (3 and 6 months,
0/37 patients) or showed a functional impairment of the
legs (3 months, 4/37 patients; 6 months, 2/37 patients),
and only 14% (5/37 patients) showed local bone/tissue
swelling (3 and 6 months, 8/37 patients) and asymmetry
of the extremities or thorax (3 months, 11/37 patients;
6 months, 8/37 patients) (Table 3).
The CNO overall disease activity was initially esti-
mated by the parents/patient as 4.7 on the VAS, after
1 month of treatment as 1.5, after 3 months as 1.1, after
6 months as 0.8, and after 12 months as 0.7 (mean 1.8
in the first year), showing a significant improvement.
Severity of disease was initially estimated by the physi-
cian as 5.0, after 1 month as 2.4, after 3 months as 1.4,
after 6 months as 1.1, and after 12 months as 0.6 (mean
2.1 in the first year), confirming the significant ameliora-
tion of complaints.
Global assessment/CHAQ was initially estimated as
3.8, after 1 month as 1.4, after 3 and 6 months as 0.8,
and after 12 months as 0.5 (mean 1.5 in the first year).
The CHAQ score was 0.7 at initial presentation, 0.3
after 1 month, 0.1 after 3 and 6 months, and 0.0 after
12 months. Global assessment/CHAQ and the CHAQ
score show a significant reduction in the follow-ups
(ANOVA, P < 0.05) (Figure 3 and Table 4). Patients
initially presenting with a higher number of radiological
and clinical lesions also presented with a higher CHAQ
score (radiological lesion - CHAQ score: P < 0.000004,
correlation coefficient r = 0.6; and clinical lesion -
CHAQ score: P < 0.0098, correlation coefficient r = 0.4).
The PedCNO score showed a similar clinical improve-
ment as the single measures (Figure 4). The percentage
of PedCNO30 at month 3 was 62%, at month 6 was
72%, and at month 12 was 62%. PedCNO50 responders
at month 3 were 59%, at month 6 were 65%, and at
month 12 were 57%. The percentage of PedCNO70
responders at month 3 was 41%, at month 6 was 51%,
and at month 12 was 54%, respectively.
Course of clinical lesions
After 3 months of treatment 12 patients (32%), after
6 months 16 patients (43%) and after 12 months
23 patients (62%) were clinically lesion free. After
12 months, four patients showed an unchanged number
of lesions (one lesion each), three patients showed a
lower number (from two to one lesions) and 11 patients
had acquired clinical relapses/new lesions during follow-
up (partially overlapping cohort). New lesions occurred
in one patient at month 1 and in five patients at month
6 as well as month 12. These new lesions involved the
extremities in 82% (9/11) of patients. Four of those
11 patients were lesion free at month 12.
Course of radiological lesions
Total numbers of radiological lesions were significantly
lower at month 6 (n = 89) and month 12 (n = 81)
(ANOVA, P < 0.05) (Table 1). Concerning the distribu-
tion of radiological lesions, only thoracic lesions at
month 12 and lesions in the spine and pelvis at
months 6 and 12 were significantly less frequent over
time (ANOVA, P < 0.05). The extremities were the
most frequently affected region at all time points. The
absolute numbers of lesions in the extremities did
decrease; however, relatively the fraction even
increased over time (Table 1). The absolute number of
lesions in the extremities changed significantly over
time (ANOVA for repeated measurements, P < 0.05),
but does not show a significant difference between the
single time points (ANOVA, P > 0.05) - most probably
Table 3 Clinical course of disease 1
Symptom 0 months 1 month 3 months 6 months 12 months Mean in first year
Morning stiffness 6 (16.2) 1 (2.7) 0 (0) 0 (0) 0 (0) 1.4
Functional impairment of legs 25 (43.2) 14 (37.8) 4 (10.8) 2 (5.4) 1 (0) 9.2
Local bone/tissue swelling 15 (40.5) 14 (37.8) 8 (21.6) 8 (21.6) 5 (13.5) 10.0
Asymmetry of extremities/thorax 14 (37.8) 12 (32.4) 11 (29.7) 8 (21.6) 5 (13.5) 10.0
Results presented as absolute numbers (%). The asymmetry of the thorax was noted predominantly due to rip and sternal involvement. This led to an
asymmetric growth and shape of the thorax.
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due to the small number of patients and the relatively
high variance.
After 3 months of treatment one patient (3%), after 6
months five patients (14%) and after 12 months 10
patients (27%) were free of radiological lesions. After
12 months, seven patients (19%) showed an unchanged
number of lesions (one to three lesions), five patients
(14%) showed a lower number and 15 patients (41%)
showed radiological relapses/new radiological lesions at
follow-ups. Four new lesions were detected at month
3, five lesions at month 6 and six new lesions at
month 12, involving the extremities in 80% (12/15
Figure 3 Clinical course of disease. Results presented as mean of scores indicated. Statistical analysis performed using analysis of variance.
CHAQ, childhood health assessment questionnaire.
Table 4 Clinical course of disease 2
Symptom 0 months 1 month 3 months 6 months 12 months Mean in first year
Severity of disease - physician 5.0 2.4a 1.4a 1.1a,b 0.6a,b,c 2.1
Severity of disease - patient 4.7 1.5a 1.1a 0.8a 0.7a,b 1.8
Pain 4.4 1.5a 0.8a 0.8a 0.6a 1.6
Global assessment/CHAQ 3.8 1.4a 0.8a 0.8a 0.5a 1.5
CHAQ score 0.7 0.3a 0.1a 0.1a,b 0a,b 0.7
Results presented as mean. Statistical analysis performed using analysis of variance. CHAQ, childhood health assessment questionnaire. aP < 0.05 versus month 0.
bP < 0.05 versus month 1. cP < 0.05 versus month 2.
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patients). In patients who showed MRI-defined relapses
(n = 15), only one was in radiologic remission before
(no radiological lesions at month 6) and only five
patients noticed these lesions clinically at the time of
the radiological relapse. Of the nine patients initially
presenting with radiological lesions in the spine, seven
patients were free of active radiological spine lesions
after 12 months. Two of the spine lesions were not
influenced by treatment.
Discussion
Laboratory features
Laboratory parameters were shown to be neither con-
sistent nor entirely predictive for a particular disease
course in CNO. Nevertheless, systemic inflammatory
markers may be raised to some extent, especially in
the multifocal disease type and in patients with asso-
ciated inflammatory bowel disease. The ESR directly
did correlate with the number of radiological lesions,
but not clinical lesions. This suggested that the quite
often clinically silent lesions can contribute to a mea-
surable systemic inflammation. Of interest, the number
of radiologically defined lesions did not strictly corre-
late with the patient-reported disease activity over
time. ANA and HLA-B27 may be present but, accord-
ing to our patients, neither was the prevalence signifi-
cantly raised compared with healthy individuals nor
were these antigens associated with a more severe
course of CNO.
Scoring the disease
No particular scores have so far been described to mea-
sure CNO disease activity. We have used conventional
tools established in the analysis of juvenile idiopathic
arthritis. The assessment of clinical response in CNO
has not so far been standardized. Using a PedCNO
score similar to the American College of Rheumatology
pediatric score score and the definition of improvement
established for juvenile idiopathic arthritis, our results
suggest a rapid clinical improvement in our cohort of
CNO patients. The lack of specific laboratory markers
in children with CNO suggests using the ESR as a bio-
chemical marker of response in the core set. Some chil-
dren in our cohort have a normal ESR throughout the
study, compromising the utility of the definition of
improvement. The severity of disease estimated by the
patient/parents as a measure to reflect functional
impairment or damage and severity of disease estimated
by the physician was included based on previous find-
ings in assessment of juvenile idiopathic arthritis. Pain
rating was discarded because it is reflected in the sever-
ity of disease estimated by the patient/parents. The
number of radiological lesions was also included as we
consider it of therapeutic relevance.
Figure 4 Course of disease: PedCNO score. Course of disease with the PedCNO30, PedCNO50 and PedCNO70 scores. Results presented as
percentages of the absolute numbers of patients.
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The CHAQ is the most widely utilized functional sta-
tus measure in pediatric rheumatology today. The
CHAQ has shown to be a valid, reliable, and sensitive
functional status measure in children with juvenile idio-
pathic arthritis [22]. The patient’s and the physician’s
global estimations of disease activity did document the
CNO course over time quite comparably, as did the
overall pain score (all on a VAS of 0 to 10). It seemed
obvious that pain is the most relevant complaint of the
patient. The global assessment, as documented in the
CHAQ, did report a disease activity comparable with
the global severity scores used.
The CHAQ score did correlate directly with the num-
ber of radiologically and clinically reported lesions at
time of diagnosis. The overall CHAQ score showed the
same course over time as the other clinical scores, but
had a smaller spectrum of absolute values. In the case
of its use in CNO, higher average age and less severe or
lack of arthritis probably influences the documented
maximum CHAQ score and the validity. Difficulty to
perform everyday activity without special aid, devices or
assistance was reported rarely, leading to lower or even
normal CHAQ levels in comparison with those in juve-
nile idiopathic arthritis. Some CNO patients may even
underestimate their disabilities and discomfort. There-
fore, even though improvement was documented in our
patients, it remains to be validated whether the CHAQ
is a reliable and sensitive functional measure in children
with CNO over the long term [23,24].
Treatment response and prognosis
In our study NSAIDs proved to be an effective therapy
concerning clinical aspects (pain, severity of disease,
general assessment, CHAQ score, number of clinical
lesions) along with a significant amelioration of physical
function and quality of life in all patients. Comparable
results have been reported before, including our own
previous cohort [12,13]. Now we describe in detail the
treatment results in the first year showing that 43% of
patients can be brought into clinical remission after
6 months and 51% after 12 months of treatment. Radi-
ological absence of lesions (remission) was noted in 14%
after 6 months and in 27% of patients after 12 months.
Data in the literature are not available for a controlled
follow-up in the first 12 months so it is hard to place
the treatment response in our patients into a historical
comparison. Since no placebo control was used, the
overall effectiveness of the treatment can only be esti-
mated. When compared with historical controls, how-
ever, an effectiveness seems obvious. Future prospective
controlled and randomized trials seem necessary in this
regard.
We had chosen to add sulfasalazine as a DMARD
after 6 months. Oral glucocorticoids were used as a
bridging agent for a limited period of time together with
the start of sulfasalazine. By using this strategy we were
able to significantly improve the clinical status of the
four patients identified as partial responders at month 6.
Nevertheless, it is obvious that the currently preferred
treatment is not able to reach remission (radiologically
defined) in the majority of patients during/after 1 year.
New MRI-defined lesions did even appear in two
patients treated with NSAIDs and sulfasalazine from
month 6 to month 12. Defining tools to identify patients
at risk for a nonresponse to treatment therefore seems
of particular relevance.
Additional use of DMARDs already at the time of
diagnosis may be helpful and should be considered espe-
cially in cases with many inflammatory MRI detectable
lesions - as those patients often show a more severe
course of disease and may not significantly profit from
NSAIDs alone. After 6 months of treatment, clinical and
radiological assessment including WB-MRI should be
performed in order to assess treatment effects, to detect
new inflammatory lesions and progressive disease in
order to evaluate therapy escalation. Determining which
DMARD might be preferable was not the aim of our
study.
In patients with a radiologically lesion-free status
(clinical and radiological remission) we did precede
according to the protocol as follows: treatment was
scheduled for another 6 weeks, and then it was discon-
tinued stepwise. Whether NSAID therapy can be
stopped in the long term in case of a radiologically
lesion-free (and in our cohort also clinically lesion-free)
status still remains to be documented in the further fol-
low-up of our cohort. Furthermore, it is important to
note that this was not a placebo-controlled study, so the
effects of treatment can only be described and the effi-
cacy estimated. Future prospective controlled and ran-
domized trials seem necessary in this regard.
Summarizing our clinical and therapeutic findings,
most children show a favorable clinical outcome in the
first year of anti-inflammatory treatment. Inflammatory
radiological lesions were still present in 32% (12/37) of
patients after 12 months. New lesions appeared in 41%
(15/37) of patients during the first year. These lesions
mostly were clinically silent, but may become sympto-
matic in the later course of disease.
MRI diagnostics
T2-weighted MRI sequences with fat-suppression tech-
niques were demonstrated to be a very sensitive diag-
nostic tool at the initial and follow-up examinations.
Aside from WB-MRI, technetium bone scans can also
be helpful in the initial diagnostic setting. Both methods
give an estimation of clinically silent CNO lesions; how-
ever, WB-MRI may not be available in all institutions.
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The region of the extremities was the most frequently
affected site at initial presentation and in relapses, and it
showed the lowest rate of improvement. Interestingly,
the fraction of lesions in the extremities was increasing
over time during follow-up, suggesting a more limited
response to NSAID treatment compared with other
locations.
New MRI-defined lesions (n = 15) did appear during
the first year (3 months, 4/15 patients; 6 months, 6/15
patients; 12 months, 5/15 patients) despite anti-inflam-
matory treatment. Whether the clinically reported com-
plaints or the MRI-defined number of lesions will be the
better predictor of the long-term outcome cannot be
determined from the 1-year follow-up. In our experi-
ence, however, persistence of lesions as defined at
12-month follow-up (by clinical complaints as well as
detected radiologically) point towards a long-term
chronic disease. Only 33% (5/15) of patients with newly
defined radiological relapses clinically did notice these
lesions in parallel, raising the question of whether the
decision for further treatment should be made mainly
by clinical complaints or by radiological data. We have
decided to consider these clinically silent lesions of ther-
apeutic relevance. In this regard it seems already
obvious that MRI is of higher sensitivity than the clinical
experience of the patient. This impression is supported
by the fact that all clinically defined and noted lesions
did have an MRI correlate. Long-term data in this pro-
spectively followed cohort may provide information
about the clinical and radiological outcome and the
therapeutic strategies to choose in this regard.
Conclusions
In summary we found a sustained response after 1 year of
anti-inflammatory treatment using NSAIDs, and in cases
of insufficient response sulfasalazine plus short-term pre-
dnisone was added with positive therapeutic effect. The
major findings of our prospective study were a rapid
improvement of disease activity, pain and physical func-
tion going along with a reduction of predominantly clini-
cal lesions but also radiological lesions. Relapses and new
radiological lesions did occur during follow-up, but may
not be recognized by the patient. WB-MRI proved to be
very sensitive for initial and follow-up diagnostics.
Additional file 1: Further information about the diagnostic
procedures mentioned in Subjects and methods. A word file
presenting more detailed information about subjects and methods.
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